Pre-clinical mechanism
Binds the pituitary GHRH receptor, stimulating endogenous growth hormone release through a pulsatile pattern resembling physiological GH secretion. The DAC (drug affinity complex) variant carries a maleimide group that reacts with serum albumin in animal models, extending plasma half-life.
Key pre-clinical findings
- Rodent and canine pharmacokinetic studies: extended half-life of the DAC variant relative to unmodified GHRH (Teichman et al., 2006).
- Healthy adult phase-1 pharmacology: dose-dependent increases in GH and IGF-1 with weekly administration (Teichman et al., 2006).
Primary literature
Research and educational use only. This page summarises publicly available pre-clinical literature for educational and scientific reference. It is not medical, clinical, dosing or therapeutic advice. Nothing on this page implies that any VCP Australia product is approved, certified, safe, effective, suitable for a particular purpose, or intended for human or animal consumption.